Immunofluorescent analysis of AKT1 + AKT2 + AKT3 showing staining in the cytoplasm and nucleus of HeLa cells. HeLa cells were fixed in ice-cold MeOH for 5 min and stained using an AKT1 + AKT2 + AKT3 polyclonal antibody (Product # PA5-31915) diluted at 1:500. Blue: Hoechst 33342 staining.
|Tested species reactivity||Human|
|Host / Isotype||Rabbit / IgG|
|Immunogen||Recombinant fragment corresponding to a region within amino acids 111 and 398 of Human AKT1+2+3|
|Purification||Antigen affinity chromatography|
|Storage buffer||PBS, pH 7, with 1% BSA, 20% glycerol|
|Storage Conditions||-20° C, Avoid Freeze/Thaw Cycles|
|Tested Applications||Dilution *|
|Western Blot (WB)||1:1000-1:10,000|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
PA5-31915 targets AKT1+2+3 in ICC/IF and WB applications and shows reactivity with Human samples.
The PA5-31915 immunogen is recombinant fragment corresponding to a region within amino acids 111 and 398 of Human AKT1+2+3.
The serine-threonine protein kinase encoded by the AKT1 gene is catalytically inactive in serum-starved primary and immortalized fibroblasts. AKT1 and the related AKT2 are activated by platelet-derived growth factor. The activation is rapid and specific, and it is abrogated by mutations in the pleckstrin homology domain of AKT1. It was shown that the activation occurs through phosphatidylinositol 3-kinase. In the developing nervous system AKT is a critical mediator of growth factor-induced neuronal survival. Survival factors can suppress apoptosis in a transcription-independent manner by activating the serine/threonine kinase AKT1, which then phosphorylates and inactivates components of the apoptotic machinery. Multiple alternatively spliced transcript variants have been found for this gene.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.